

4.0.03 DOC Cmte minutes

Thyroid cancer Committee meeting 7

Date: 26/05/21 10:00-16:00

Location: Virtual meeting

Minutes: Confirmed

NICE National Institute for
Health and Care Excellence

Committee members present:		
Richard Grünewald [RG] – Chair		(Present for notes 1 – 5)
Jeremy Davis [JD] – Topic advisor		(Present for notes 1 – 5)
John Buscombe [JB]		(Present for notes 1 – 5)
Preetha Chengot [PC]		(Present for notes 1 – 5)
Neil Cozens [NC]		(Present for notes 1 – 5)
Fiona Eatock [FE]		(Present for notes 1 – 5)
Kate Farnell [KF]		(Present for notes 1 – 5)
Steve Hyer [SH]		(Present for notes 1 – 5)
Jessica Lishak [JL]		(Present for notes 1 – 5)
Kate Newbold [KN]		(Present for notes 1 – 5)
Sonja Hoy [SH]		(Present for notes 1 – 5)
Iain Nixon [IN]		(Present for notes 1 – 5)
Anh Tran [AT]		(Present for notes 1 – 5)

In attendance:		
Carlos Sharpin [CS]	Guideline Lead	(Present for notes 1 – 5)
Mark Perry [MP]	Senior Research Fellow	(Present for notes 1 – 5)
Alfredo Mariani [AM]	Health Economist	(Present for notes 1 – 5)
Kevin Galbraith [KG]	Research Fellow	(Present for notes 1 – 5)
Lina Gulhane [LG]	Head of Information Specialists	(Present for notes 4 – 5)
Giulia Zuodar	Project Manager	(Present for notes 1 – 5)

Apologies:	
Jessica Lishak [JL]	GC member
Catrina Charlton [CC]	NICE Guideline Commissioning Manager
Mark Perry [MP]	Senior Research Fellow

4.0.03 DOC Cmte minutes

1. Welcome and objectives for the meeting

The Chair welcomed the Committee members and attendees to the seventh meeting on Thyroid cancer. The Committee members and attendees introduced themselves.

The Chair outlined the objectives of the meeting, which included:

- RAI vs no RAI
- discussing protocols on:
 - molecular testing
 - measuring thyroglobulin
 - preventing risk of recurrence
 - indications for imaging

2. Confirmation of matter under discussion, and declarations of interest

The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was RAI vs no RAI, molecular testing, measuring thyroglobulin, preventing risk of recurrence, indications for imaging.

No new declarations were received.

The Chair and a senior member of the Developer's team noted that the interests previously declared did not prevent the attendees from fully participating in the meeting.

3. Evidence review: RAI vs no RAI

KG/AM presented the evidence for RAI vs no RAI. The GC drafted recommendations.

4. Draft protocols

KG presented draft protocols:

- molecular testing
- measuring thyroglobulin

4.0.03 DOC Cmte minutes

<ul style="list-style-type: none">• preventing risk of recurrence• indications for imaging
5 Any other business
None.

Date of next meeting:

5&6 July 2021

Location of next meeting: Virtual meeting